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& Abstract
Objective: During implantation of a neuromodulative sys-
tem, high patient satisfaction is closely associated with the
equilibrium between an effective analgesia and sedation
regimen, and the possibility for the patient to be awake and
cooperative during procedure. This study assessed the effi-
cacy of the sedative dexmedetomidine to achieve this
balance, with patient satisfaction as the primary outcome.
Methods: Ten patients undergoing implantation of a dorsal
column and dorsal root ganglion stimulator received
dexmedetomidine (1 mcg/kg over 10 minutes, followed by
0.6 mcg/kg/hour) in combination with remifentanil at a set
dose (3 mcg/kg/hour). Sedation was titrated to a Ramsay
Sedation Score of 3. Recorded were as follows: patient
satisfaction score, patient comfort score, operator comfort
score, pain score, rescue medication and number of adjust-
ments of dexmedetomidine intra-operatively, as well as
sedation level, hemodynamic (blood pressure and heart rate),
and respiratory characteristics (SpO2).
Results: Scores were high on patient satisfaction (median
8.5; IQR 2.0), patient comfort (3.0; IQR 1.25), and operator
comfort (4.0; IQR 1.0). In all patients, intra-operative heart
rate and mean arterial pressure were lower compared with
baseline values. No respiratory depression or other compli-
cations related to anesthesia were reported. Moments of
incident pain were effectively treated in 6 patients requiring
an extra bolus of remifentanil.
Conclusion: In this study group, dexmedetomidine com-
bined with remifentanil provided a high level of patient
satisfaction and comfort, as well as operator comfort, with-
out any clinically relevant adverse events. All patients were
highly cooperative and instructable; incident pain needs to
be closely monitored. &
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INTRODUCTION
To place neurostimulation leads, most of the currently
available systems require the cooperation of the patient.
The overlap between neurostimulation-induced pares-
thesia and the pain area can only be specified by the
patient. For patients, the procedure can be frightening,
uncomfortable (due to theprolongedproneposition), and
sometimes painful due to inadequate analgesia. There-
fore, adequate information and guidance is essential. In
addition, besides local anesthesia, the use of anxiolytics,
sedatives, and more general analgesics can be helpful.
However, a potential disadvantage of these adjuvants is
that, due to the sedative effect of these drugs, patientsmay
be insufficiently cooperative with the instructions and
questions posed by physicians and nurses.
A promising analgosedative is dexmedetomidine, a
highly selective, long-lasting presynaptic a2-receptor
agonist with sedative, anxiolytic, and analgetic
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properties. With dexmedetomidine, there is no decline
of cooperation or of cognitive skills. Due to its
pharmacologic profile, dexmedetomidine acts on the
a2 receptors in the locus coeruleus, in contrast to other
sedatives which act on GABA receptors/cerebral cortex
(eg, midazolam and propofol), and there is no respira-
tory depression. Furthermore, in combination with
intravenous opioids (such as remifentanil), dexmedeto-
midine allows for lower doses of opioids. Earlier
randomized controlled trials evaluating the use of
dexmedetomidine alone during small diagnostic and
therapeutic procedures showed promising results1–3.
However, a potential disadvantage of dexmedetomidine
is its hemodynamic side effects, which include hypoten-
sion and bradycardia.4,5
Therefore, this study aimed to examine the applica-
bility of dexmedetomidine for the placement of neu-
rostimulation leads for procedures in which the patient’s
cooperation is required. Applicability is operationalized
as measurement of patient satisfaction, patient and
operator’s comfort, pain relief and rescue medication,
the number of adjustments made to the administration
of dexmedetomidine, sedation level, and hemodynamic
and respiratory monitoring.
METHODS
Study Design, Selection of Patients
The study protocol was approved by the Medical Ethics
Committee of Erasmus Medical Center and registered
with the Netherlands Clinical Trials Registry (NL
49012.078.12).
This is a proof-of-concept, prospective observational
study. After providing informed consent, we enrolled 10
consecutive patients (aged 18 to 65 years) with an
indication for trial implantation of a neurostimulation
system, for which cooperation of the patient during lead
placement is required. Exclusion criteria included hyper-
sensitivity to either of the drugs involved, atrioventric-
ular block (II–III), acute cerebrovascular disease, heart
rate ≤ 60 bpm, pregnancy, acute epilepsy, severe liver
dysfunction, use of beta blocking agents, psychological
instability, and/or a communication problem.
Study Site, Measurements
Before the procedure, all patients received standard
education and were guided perioperatively by a nurse.
All patients were commenced on a dexmedetomidine
infusion in the operating room, using an intravenous
cannula. Sedation was performed by an independent
anesthesiologist not involved in the interventional pro-
cedure. Implantation of the neuromodulative system
was performed by another anesthesiologist-pain special-
ist not involved in the sedation. An independent
observer, not involved in the sedation or the interven-
tional procedure, performed all study measurements.
During each procedure, measurements were made at 7
predefined moments: a preoperative measurement, at
start of dexmedetomidine, at start of remifentanil, at
start of the procedure, at midline incision (incision of the
skin for anchoring the lead on the subcutaneous fascia
and subcutaneous tunneling of the lead), at end of the
procedure, and postoperatively on the ward.
Patients were administered a loading dose of
dexmedetomidine of 1 mcg/kg over 10 minutes to
achieve the required level of sedation according to the
Ramsay Sedation Scale6 (score 2 to 3) (Table 1). This
scale was used before the initiation of sedation and at 5-
minute intervals until the end of the procedure. The dose
was adjusted depending on the required level of sedation
(ie, a Ramsay score of 2 when the patient is required to
be cooperative, and a score of 3 to 4 when the patient
requires increased sedation). The maintenance dose of
dexmedetomidine is 0.1 to 1.4 mcg/kg/hour; in the
present study, a maintenance dose of 0.6 mcg/kg/hour
was used.
Ten minutes after commencement of the loading dose
of dexmedetomidine, remifentanil infusion was started
at a set dose (3 mcg/kg/hour) to achieve a high analgesic
effect. Standard care involves the use of 1% lidocaine in
combination with adrenaline (1:200,000) at the start of
the procedure, during the midline incision, and at end of
the procedure.When a patient complained of pain during
the procedure, the anesthesiologist administered an
additional bolus of remifentanil (25 to 50 mcg/kg/hour).
Our primary outcome parameter was patient satis-
faction, as measured with a postoperative overall patient
Table 1. Details of the Ramsay Sedation Scale
Clinical Score Level of Sedation
1 Patient is anxious and agitated or restless or both
2 Patient is cooperative, oriented and tranquil
3 Patient responds on command
4 Patient exhibits a brisk response to a light glabellar
(between the eyebrows) tap or loud auditory stimulus
5 Patient exhibits a sluggish response to a light glabellar
tap or loud auditory stimulus
6 Patient exhibits no response to stimulus
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satisfaction questionnaire (consisting of 7 questions)
(Table 2).6 Secondary outcomes were pain relief,
patient’s comfort and operator’s comfort (using a
comfort score) (Table 3)4, number of adjustments made
during dexmedetomidine titration, scores on the Ram-
say Sedation Scale, and intra-operative standard mon-
itoring including noninvasive mean arterial pressure
(MAP), heart rate (HR) via ECG, pulse oximetry (spO2),
and end tidal CO2 (EtCO2).
Data Analysis
At each measurement moment, mean values of the
outcomes were collected and reported as outcome per
time moment. These values differ for each measurement
moment, depending on the duration of the procedure, as
measurements are made every 5 minutes.
Statistical Analysis
Descriptive statistics were used to determine the fre-
quencies of the demographic variables and the outcome
parameters, and to describe measures of central ten-
dency and of variability, depending on the shape of the
distribution. All analyses were performed using IBM
SPSS Statistics version 21 (Armonk, NY, USA).
RESULTS
A total of 10 patients were included (Table 4).
All patients completed the study; the median score of
patients’ overall satisfaction was 8.5 (IQR, 2.0)
(Table 5). All patients reported to be awake during the
implantation and 20% experienced the procedure as
stressful. In case of a repeat procedure, all patients stated
they would request the same anesthetic procedure again.
None of the patients reported complications related to
the anesthesia. The median score for patient comfort
was 3.0 (IQR, 1.25), and for operators’ perioperative
comfort, it was 4.0 (IQR, 1.0).
In case of unacceptable pain management, patients
received a bolus of remifentanil of 25 mcg/kg/hour. Six
patients required an extra bolus of remifentanil during
insertion of the Tuohy needle, or during subcutaneous
tunneling. One patient needed 1 bolus of remifentanil, 3
patients received 2 boluses, and 2 patients needed ≥ 3
boluses. During the procedure, only 1 patient needed an
increase of 0.2 mcg/kg/hour dexmedetomidine to
achieve an adequate sedation level.
Median SBP, DBP, MAP, and mean HR decreased
during the procedure (Figures 1 and 2); however, none
of these changes were clinically relevant. No patient
required any airway intervention.
The mean duration of the procedure was 115.4 (SD
34.84) minutes, and the median duration was 118.5
(IQR, 56.25) minutes.
DISCUSSION
When a patient is required to be awake during a surgical
procedure, this is generally experienced as a stressful and
uncomfortable situation. Therefore, an effective sedo-
analgesic regimen is necessary. During implantation of a
neuromodulative system (classified as a small therapeu-
tic procedure), patients need to be cooperative and able
to follow instructions. Dexmedetomidine may be useful
for this clinical situation, as its benefits have been
Table 2. Patient Satisfaction Questionnaire
Q1 On a scale from 1 to 10 (1 least satisfied, 10 most satisfied), how
satisfied were you with your anesthesia during your operation?
Q2 Do you remember awakening during the procedure?
Q3 If yes, was the experience distressful?
Q4 If you were to have the operation again, would you choose the
same anesthesia?
Q5 Do you recall problems at home after discharge with anesthesia
(hangover)?
Q6 Do you know of any complications from the anesthetic used?
Q7 If yes, what complications?
Table 3. Patient Comfort Score and Operator Comfort
Score
Criteria Score
Excellent 4
Good 3
Fair 2
Poor 1
Table 4. Details of the Included Patients
Variables Patients (n = 10)
Age in years (median; IQR) 53.5; 17,75
Female gender, n (%) 7 (70%)
BMI (kg/m2): mean (SD) 28.47 (4.35)
Table 5. Data on Overall Patient Satisfaction
Patient satisfaction (median; IQR) 8.5; 2.0
Awake Yes (100%)
Stressful Yes (20%)
Would choose same anesthesia again? Yes (100%)
Home problems Not applicable
Were there complications related to anesthesia? No (100%)
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reported in various types of procedures.7,8In the present
study, patients reported a high level of satisfaction
(median 8.5; IQR 2.0). Moreover, all patients would
choose the same anesthesia regimen again in case of
future comparable interventions, and only 20% experi-
enced the implantation as a stressful procedure. Patient
comfort was good (median 3.0; IQR 1.25), and operator
comfort was excellent (median 4.0; IQR 1.0).
During the procedure, scores on the Numeric Rating
Scale (NRS) decreased in nearly all patients, demon-
strating adequate pain relief using dexmedetomidine in
combination with remifentanil. However, dexmedeto-
midine is not suitable for incident pain. In our study,
incident pain occurred during insertion of the Tuohy
needle or tunneling, during which pain scores rose to 8
to 10. This was dealt with by administering a bolus of
remifentanil of 25 mcg/kg/hour before the start of
tunneling, or a comparable procedure.
In the postoperative period, heart rate and saturation
went down (Figures 2 and 3); however, the pain score
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Figure 1. Median, systolic and diastolic
arterial blood pressure at eachmeasure-
ment.
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Figure 2. Mean heart rate at each
measurement.
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increased. This might be due to the fact that the patient
was not experiencing fear any more after the procedure
(HR decreased) and did not get any oxygen support
(saturation). The decrease in HR and saturation were
not clinically relevant. Pain score increased postopera-
tively probably because of pain around the wound,
made during surgery. The neuromodulative system was
not active at that moment.
This proof-of-concept study demonstrates that a
sedation regimen of dexmedetomidine and remifentanil
allows implantation of a neuromodulative without the
need for airway support. Safety during a procedure
depends on airway tone, and controlling this factor will
potentially increase patient safety. In our study, airway
stability was maintained and no respiratory depression
in prone position was observed. This latter result was
expected, because dexmedetomidine does not act on
GABA receptors.9
During all procedures, hypotension and bradycardia
were observed in all patients (Figures 1 and 4), but
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Figure 3. Median oxygen saturation
level (SpO2) at each measurement.
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Figure 4. Mean Numeric Rating Scale
(NRS) pain score at each measurement.
212  TER BRUGGEN ET AL.
stayed within an acceptable range. No patient required
atropine or any form of hemodynamic support. Patient
cooperation and level of instructability were excellent
during all procedures. Patients were asleep during the
procedure but awakened immediately upon hearing a
verbal command. During the procedure, patients had a
Ramsay score of 2 to 3 when using a loading infusion of
1 mcg/kg/hour for 10 minutes and a maintenance dose
of 0.6 mcg/kg/hour for the remainder of the procedure;
this is the desired level of sedation. During the entire
procedure, a set dose of remifentanil of 3 mcg/kg/hour
was administered. Moreover, the use of dexmedeto-
midine allowed to use a lower set dose of remifentanil as
compared with standard care.
The use of dexmedetomidine in neuromodulation
surgery including deep brain stimulation (DBS) is well
described. Outcomes show promising results, such as
good surgical conditions, patient comfort, and analge-
sia. Furthermore, dexmedetomidine provided a compa-
rable hemodynamic stability during DBS implantation
and this trial.10,11 A limitation of the present study is
that we used an observational design with a small
sample size, because our first aim was to examine the
applicability of dexmedetomidine. Furthermore, we did
not add the management of bradycardia in the study
protocol because this is part of standard care. Any form
of hemodynamic support using atropine was not neces-
sary. A follow-up study will compare dexmedetomidine
with more conventional regimens of sedation, as well as
its cost-effectiveness.
CONCLUSION
In summary, in this patient group, dexmedetomidine
combined with remifentanil provided a high level of
patient satisfaction and comfort, as well as good
operator comfort, without any clinically relevant
adverse events. All patients were asleep during the
procedure, but were highly cooperative and instructable
when required; moreover, there was no report of
respiratory depression. A randomized controlled trial
is required to further investigate the role of dexmedeto-
midine for the implantation of a neuromodulative
system.
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